EAU 2018

EAU 2018: Assessing Irrigation Flows Influence on Clearance of Renal Calculi Fragments During PCNL: A Hydrodynamic Computerized and Practical Model Study

Copenhagen, Denmark (UroToday.com) Dr. Dekalo, clinical urologist from the Tel-Aviv Sourasky Medical Center in Tel-Aviv, Israel, presented a continuative study on a previous finding regarding the usefulness of irrigation flows within a kidney model. Recent findings suggest that that irrigation flow contributes to the improvement of endoscopic vision while also flushing out of stone fragments created during percutaneous nephrolithotomy (PCNL). The study that came to this realization used a kidney model of a single calyx to determine the effectiveness of irrigation. Dr. Dekalo expressed his concerns with this study since it did not accurately represent the intrarenal collecting system of a human kidney. For this reason, Dr. Dekalo and his team aimed to further analyze the processes of irrigation and the potential benefits they hold in a computerized model (CM) and PCNL practice model (PM). 

EAU 2018: Debate: Single-Use Flexible Ureteroscopy: Ready to Become Standard?

Copenhagen, Denmark (UroToday.com) In recent literature and practice, there have been expanding indications for the use of flexible ureteroscopy (URS), including those of proximal ureteral stones, intra-renal stones, lower pole stones (<1.5 cm) and upper tract urothelial cell carcinomas. Due to the increase in use, however, single-use flexible URS have emerged as an alternative to reusable scopes – both for efficiency in turn-over and for potential cost savings.

EAU 2018: Precision Medicine in Renal Cell Cancer, Can We Select The Treatment?

Copenhagen, Denmark (UroToday.com) Dr. Alessandro Volpe provided a discussion on precision medicine for patients with renal cell cancer. Precision medicine is a medical model that proposes the customization of healthcare with medical decisions, treatment and practices tailored to the individual patient. Precision medicine, specifically in patients with high risk/advanced/metastatic RCC, includes (i) selection of the optimal targeted/immunotherapy, (ii) indications for adjuvant therapy after radical nephrectomy, and (iii) indications for cytoreductive nephrectomy in the setting of metastatic RCC. Precision medicine, specifically in patients with localized RCC, includes (i) indications for nephron-sparing surgery in larger tumors (T1b-T2), (ii) indications for lymph node dissection in high-risk disease, and (iii) indications for non-surgical management in select patients. 

EAU 2018: Molecular Heterogeneity Between Primary Tumors and Metastases in Renal Cell Cancer

Copenhagen, Denmark (UroToday.com) Dr. Kerstin Junker from Germany discussed the molecular heterogeneity between primary tumors and metastases. According to Dr. Junker there are three types of tumor heterogeneity, including (i) intertumor heterogeneity, (ii) intratumor heterogeneity, and (iii) heterogeneity between primary tumors and metastases. Understanding the heterogeneity of metastatic disease allows selection of therapy targets and prediction of therapy responses. 

EAU 2018: Molecular and Histopathological Heterogeneity in Muscle-Invasive Bladder Cancer

Copenhagen, Denmark (UroToday.com) Dr. Antonio Lopez-Beltran from Spain gave a talk on molecular and histopathological heterogeneity in muscle invasive bladder cancer (MIBC). Dr. Lopez-Beltran started by highlighting that urothelial carcinoma has two morphologic and molecular phenotypes: non-muscle invasive bladder cancer (NMIBC; 70-80%) and MIBC (20-30%). 

EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? YES

Copenhagen, Denmark (UroToday.com) Dr. Armin Pycha from Bolzano, Italy provided the “yes” argument for ureterocutaneostomy in critically ill patients with locally advanced bladder cancer. 

EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? NO

Copenhagen, Denmark (UroToday.com) Dr. Siemer from Germany provided the rebuttal to Dr. Pycha’s “yes” for ureterocutaneostomy in the critically ill patients with locally advanced bladder cancer. As Dr. Siemer notes, when treating the critically ill patient there is a balance between survival and quality of life/potential complications.